Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients
- Conditions
- Endometrial Cancer
- Registration Number
- NCT06148129
- Lead Sponsor
- Zagazig University
- Brief Summary
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society of Gynaecological Oncology -European Society for Radiotherapy \& Oncology (ESMO-ESGO- ESTRO) could guide the need for lymph node surgery pre-operatively, and also post-operatively to determine adjuvant treatment.
Low-risk patients are managed with surgery alone, while higher-risk group patients undergo more aggressive surgical options. So, it is important to identify new prognostic markers for better stratification of patients to avoid under- or over treatment of EC patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 96
- aged 36 -72 years;
- Previously diagnosed with endometrial carcinoma;
- Histological Type of the tumor;
- Myometrial Invasion;
- lymph Node Invasion;
- Cervical Invasion;
- Biomarkers expression.
- Lack of tumor tissue in tissue block
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method expression levels of p53/L1CAM/ER/PR 36 Months The Prognostic value of immunohistochemical detection of expression levels of p53/L1CAM/ER/PR in relation to ESMO-ESGO-ESTRO risk groups
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zagazig university
🇪🇬Zagazig, Ash Sharqia Governorate, Egypt
Zagazig university🇪🇬Zagazig, Ash Sharqia Governorate, Egypt